Table 2 Clinical remission in JIA patients treated with DMARD according to treatment group. Retrospective study results
|  | SDMARD alone n = 106 (53%) | SDMARD combined n = 37 (19%) | SDMARD BDMARD combined n = 48 (24%) | BDMARD alone n = 8 (4%) | Clinical remission n = 199 | p |
|---|---|---|---|---|---|---|
JIA ILAR category a n (%) | ||||||
 Oligoarticular | 66 (62) | 18 (49) | 25 (52) | 3 (1) | 112 (56) | 0.003 |
  Persistent | 61 (92) | 13 (72) | 17 (68) | 1 (33) | 92 (82) |  |
HLA B27 absence a n (%) | 89 (84) | 33 (89) | 25 (52) | 6 (75) | 153 (85) | 0,023 |
Synthetic DMARD a n (%) | ||||||
 Metotrexate | 78 (74) | 18 (49) | 15 (31) | 0 | 108 (54) | < 0.001 |
No AE with DMARD a n (%) | 81 (76) | 24 (65) | 33 (69) | 1 (13) | 139 (70) | 0.005 |
Dose tapering n = 132 | ||||||
 Dose tapering a n (%) | 80 (75) | 18 (49) | 29 (60) | 5 (62) | 132 (66) | 0,018 |
  Tapering method n (%) |  |  |  |  |  | 0,071 |
   Interval increase | 35 (44) | 8 (44) | 12 (41) | 5 (100) | 60 (45) |  |
   Dose decrease | 30 (37) | 7 (39) | 15 (31) | 0 | 46 (35) |  |
   Both | 15 (19) | 3 (17) | 1 (3) | 0 | 19 (14) |  |
  Tapering duration, months, median (IQR) | 15 (20) | 14 (27) | 21 (25) | 40 (30) | 16 (28) | 0,190 |
  Relapse amid tapering, n (%) | 10 (13) | 5 (28) | 4 (14) | 0 | 19 (14) | 0,330 |
  Withdrawal after tapering a, n (%) | 69 (86) | 16 (89) | 10 (34) | 1 (13) | 95 (72) | < 0,001 |
Withdrawal due to CR n = 124 | ||||||
 Withdrawal due to CR | 71 (67) | 29 (78) | 21 (44) | 3 (38) | 124 (62) | 0,728 |
  Treatment duration to withdrawal due to RC a, months, median (IQR) | 31 (26) | 42 (43) | 34 (54) | 68 (71) | 31 (30) | 0,037 |
  Relapse after withdrawal n (%) | 50 (70) | 16 (55) | 11 (52) | 2 (67) | 79 (64) | 0,783 |
  Time to relapse, months, median (IQR) | 13 (25) | 42 (41) | 10 (18) | 14 | 14 (32) | 0,122 |